Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
37 hedge funds and large institutions have $234M invested in Verona Pharma in 2021 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 6 closing their positions.
0% more funds holding
Funds holding: 37 → 37 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0.38% less ownership
Funds ownership: 8.3% → 7.91% (-0.38%)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
23% less capital invested
Capital invested by funds: $305M → $234M (-$71.1M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
89% less call options, than puts
Call options by funds: $4K | Put options by funds: $35K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.73M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$788K |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$423K |
| 4 |
CPIG
Chicago Partners Investment Group
Chicago,
Illinois
|
+$69.4K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$23.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$693K |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$535K |
| 3 |
HS
HighVista Strategies
Boston,
Massachusetts
|
-$306K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$153K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$126K |
VRNA Hedge Fund Activity: Q2 2021 in Review
37 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q2 2021, worth a combined $234M — down 23% from $305M a quarter earlier.
Fund positioning in VRNA was balanced in Q2 2021: 6 funds opened new positions, 6 closed out, 5 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $1.73M. The largest seller was Polar Capital Holdings, cutting an estimated $693K.
- 37 institutional investors held Verona Pharma (VRNA) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $234M of Verona Pharma stock for Q2 2021, down 23% quarter-over-quarter.
- 6 funds opened new Verona Pharma positions in Q2 2021 and 6 closed out, a net change of 0 holders.
- The largest Verona Pharma buyer in Q2 2021 was BlackRock, an estimated $1.73M added.
- The largest Verona Pharma seller in Q2 2021 was Polar Capital Holdings, an estimated $693K sold.
Based on aggregated 13F filings for Q2 2021.